{
  "ticker": "CMB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02963443",
  "id": "02963443",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250630",
  "time": "0923",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250630/pdf/06l7rw9nfkyvm5.pdf",
  "summary": "- **Key Clinical Trial Approvals**: Ethics approval granted in Australia (26 June 2025) and the U.S. (9 May 2025) for Phase 3 trials of **Elate Ocular\u00ae** for dry eye disease.  \n- **Timeline**: First patient dosing expected October 2025; top-line data anticipated Q3 2026.  \n- **Trial Design**: Global Multi-Regional Clinical Trial (MRCT) with ~800 patients across two studies (CAMOMILE-2, CAMOMILE-3).  \n- **Regulatory Path**: Supports future Biologics License Application (BLA) submission.  \n\n*No material financial or capital markets impacts (e.g., funding, dilution) disclosed.*",
  "usage": {
    "prompt_tokens": 1301,
    "completion_tokens": 152,
    "total_tokens": 1453,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-29T23:31:52.275322"
}